Global Cord Blood Corporation (CORBF)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CNY m | 1,221 | 1,160 | 1,243 | - | - | - | 1,225 | 727 |
| Operating profit | CNY m | 609 | 594 | ||||||
| Net profit | CNY m | 471 | 508 | 501 | - | - | - | 471 | 159 |
| EPS reported | CNY | 4.12 | 3.89 | ||||||
| Operating cashflow per share | CNY | 5.05 | 5.05 | ||||||
| Capex per share | CNY | 0.16 | 0.16 | ||||||
| FCF per share | CNY | 4.89 | 4.89 | ||||||
| Free cash flow | CNY m | 594 | 181 | ||||||
| Net debt | CNY m | -6,661 | -7,063 | ||||||
| Book value equity | CNY m | 4,879 | 5,174 | ||||||
| Book value per share | CNY | 40.14 | 42.49 | ||||||
| Number of shares | m | 121.55 | 121.76 | ||||||
| DPS (TTM paid) | CNY | 0.00 | 0.00 |
Financial summary
Financials in CNY| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | 2026E | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | 5.93 | 1.58 | ||||||
| P/B LTM | x | 0.61 | 0.16 | ||||||
| P/S LTM | x | 2.39 | 0.69 | ||||||
| P/FCF LTM | x | 5.00 | 1.44 | ||||||
| EV/EBITDA LTM | x | -5.62 | -8.84 | ||||||
| EV/Sales LTM | x | -2.97 | -4.67 | ||||||
| Earnings Yield LTM | % | +16.86% | +63.29% | ||||||
| FCF Yield | % | +20.01% | +21.22% | ||||||
| Quality | |||||||||
| ROE | % | +10.27% | +10.82% | ||||||
| ROIC | % | +6.26% | +6.26% | ||||||
| Operating margin | % | +48.97% | +48.97% | ||||||
| Gross margin | % | +85.26% | +85.26% | ||||||
| FCF/Sales | % | +47.76% | +47.76% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | -1.44% | - | ||||||
| Sales Growth YoY | % | +7.21% | - | ||||||
| Net Income Growth YoY | % | -1.41% | - | ||||||
| FCF Growth | % | -2.62% | - | ||||||
| Operating Profit Growth | % | +11.75% | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | 0.00% | 0.00% | ||||||
| FCF/Debt | x | 4,039.59 | 1,173.04 | ||||||
| Net Debt/EBITDA | x | -10.14 | -10.14 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +0.00% | +0.02% | ||||||
| Net debt/Equity | x | -1.37 | -1.37 | ||||||
| Gross debt/equity | x | 0.00 | 0.00 | ||||||
Price target estimates
Based on consensus from external analysts. Not Kvantra's opinion.
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
ESG
| Metric | 2024 | 2025 | 2026 |
|---|---|---|---|
| ESG-score | |||
| Environmental score | |||
| Social score | |||
| Governance score | |||
| Risk rating |
Company overview
Global Cord Blood Corporation, headquartered in Central, Hong Kong, primarily offers umbilical cord blood preservation and related support services within the People's Republic of China. The company's operations include the comprehensive testing, processing, and long-term storage of cord blood samples for its individual clients. Additionally, it undertakes the examination, preparation, and storage of donated cord blood units, facilitating their use for matching purposes. As of March 31, 2022, the corporation oversaw the management of three distinct cord blood banks, located in Beijing municipality, Guangdong province, and Zhejiang province. The entity previously operated as China Cord Blood Corporation, adopting its current name in March 2018, and functions as a subsidiary of Blue Ocean Structure Investment Company Ltd.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Global Cord Blood Corporation (CORBF)
No price history available.
Consensus from external analysts. Not Kvantra's opinion.
Based on consensus from external analysts. Not Kvantra's opinion.
Global Cord Blood Corporation, headquartered in Central, Hong Kong, primarily offers umbilical cord blood preservation and related support services within the People's Republic of China. The company's operations include the comprehensive testing, processing, and long-term storage of cord blood samples for its individual clients. Additionally, it undertakes the examination, preparation, and storage of donated cord blood units, facilitating their use for matching purposes. As of March 31, 2022, the corporation oversaw the management of three distinct cord blood banks, located in Beijing municipality, Guangdong province, and Zhejiang province. The entity previously operated as China Cord Blood Corporation, adopting its current name in March 2018, and functions as a subsidiary of Blue Ocean Structure Investment Company Ltd.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free